Liver Cirrhosis Therapeutics Drugs Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

Coverage: Liver Cirrhosis Therapeutics Drugs Market covers analysis By Type (Hepatitis C-related Cirrhosis, Alcoholic Cirrhosis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Others); Stage type (Compensated cirrhosis, Decompensated cirrhosis); Drug Type (Ursodeoxycholic acid, Obeticholic acid, Azathioprine, Colchicine, Others); Route of Administration (Oral, Intravenous, Others); End User (Hospitals, Homecare, Specialty Clinics, Others) , and Geography (North America, Europe, Asia Pacific, and South and Central America)

Publication Month : Apr 2024

  • Report Code : TIPRE00018831
  • Category : Pharmaceuticals
  • Status : Upcoming
  • No. of Pages : 150
Inquire Before Buy

PRICING

$5190

$4671

MARKET INTRODUCTION

Liver Cirrhosis is the late stage of liver fibrosis caused mainly by various liver diseases such as hepatitis, liver damage and chronic alcoholism. Every time liver injures by disease or alcoholism then it tries to repair by itself but in cirrhosis the repair cannot possible and the condition becomes threatening. The symptoms of cirrhosis includes, loss of appetite, nausea, fatigue, easy bleeding, jaundice etc. Liver cirrhosis therapeutics are the therapeutic agents which are used in the treatment of liver cirrhosis.

MARKET DYNAMICS

The key market drivers for Liver Cirrhosis Therapeutics Drugs Market Includes, rising incidences of hepatic disease and disorders along with growing geriatric population across the globe. Moreover, changing lifestyle factors such as chronic alcoholism, unhealthy eating is also expected to fuel market growth. Additionally, presence of strong pipeline for therapeutic agents is also expected to boost market growth. Whereas, patent expiration, stringent government regulations and side effects associated with the treatment is expected to restrain market growth during forecast period.

MARKET SCOPE

The "Liver Cirrhosis Therapeutics Drugs Market" is a specialized and in-depth study of the Pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Liver Cirrhosis Therapeutics Drugs market with detailed market segmentation by type, stage type, drug type, route of administration, end user. The Liver Cirrhosis Therapeutics Drugs Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Liver Cirrhosis Therapeutics Drugs Market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Liver Cirrhosis Therapeutics Drugs Market is segmented on the basis of type, stage type, drug type, route of administration, end user. On the basis of type the market is segmented as, hepatitis C related cirrhosis, alcoholic cirrhosis, primary biliary cirrhosis and others. On the basis of stage type the market is segmented as, compensated and decompensated cirrhosis. On the basis of drug type the market is segmented as, ursodeoxycholic acid, obeticholic acid, azathioprine, colchicine and others. On the basis of route of administration the market is segmented as, oral, intravenous and others. And on the basis of end user the market is segmented as, hospitals, homecare, specialty clinics and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Liver Cirrhosis Therapeutics Drugs Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Liver Cirrhosis Therapeutics Drugs Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Liver Cirrhosis Therapeutics Drugs Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Liver Cirrhosis Therapeutics Drugs Market in these regions.

World Geography

Have a question?

Analyst

Akshay

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst   Speak to Analyst
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities
MARKET PLAYERS


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Liver Cirrhosis Therapeutics Drugs Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Liver Cirrhosis Therapeutics Drugs Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Liver Cirrhosis Therapeutics Drugs Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Liver Cirrhosis Therapeutics Drugs Market in these regions.

MARKET PLAYERS

The report covers key developments in the Liver Cirrhosis Therapeutics Drugs Markets organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Liver Cirrhosis Therapeutics Drugs Market are anticipated to have lucrative growth opportunities in the future with the rising demand for, Liver Cirrhosis Therapeutics Drugs market in the global market. Below mentioned is the list of few companies engaged in the Liver Cirrhosis Therapeutics Drugs Market.

The report also includes the profiles of key players in Liver Cirrhosis Therapeutics Drugs Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.
- Gilead Sciences, Inc.
- Intercept Pharmaceuticals, Inc.
- Dova Pharmaceuticals
- GlaxoSmithKline Plc.
- Regeneron Pharmaceuticals
- Mylan N.V
- Sanofi S.A
- Teva Pharmaceutical Industries, Ltd.
- F. Hoffmann-La Roche Ltd.
- Boehringer Ingelheim International GmbH
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Liver Cirrhosis Therapeutics Drugs Market - By Type
1.3.2 Liver Cirrhosis Therapeutics Drugs Market - By Stage type
1.3.3 Liver Cirrhosis Therapeutics Drugs Market - By Drug Type
1.3.4 Liver Cirrhosis Therapeutics Drugs Market - By Route of Administration
1.3.5 Liver Cirrhosis Therapeutics Drugs Market - By End User
1.3.6 Liver Cirrhosis Therapeutics Drugs Market - By Region
1.3.6.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. LIVER CIRRHOSIS THERAPEUTICS DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. LIVER CIRRHOSIS THERAPEUTICS DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. LIVER CIRRHOSIS THERAPEUTICS DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. LIVER CIRRHOSIS THERAPEUTICS DRUGS - GLOBAL MARKET OVERVIEW
6.2. LIVER CIRRHOSIS THERAPEUTICS DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE

7. LIVER CIRRHOSIS THERAPEUTICS DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. HEPATITIS C-RELATED CIRRHOSIS
7.3.1. Overview
7.3.2. Hepatitis C-related Cirrhosis Market Forecast and Analysis
7.4. ALCOHOLIC CIRRHOSIS
7.4.1. Overview
7.4.2. Alcoholic Cirrhosis Market Forecast and Analysis
7.5. PRIMARY SCLEROSING CHOLANGITIS
7.5.1. Overview
7.5.2. Primary Sclerosing Cholangitis Market Forecast and Analysis
7.6. PRIMARY BILIARY CIRRHOSIS
7.6.1. Overview
7.6.2. Primary Biliary Cirrhosis Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. LIVER CIRRHOSIS THERAPEUTICS DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - STAGE TYPE
8.1. OVERVIEW
8.2. STAGE TYPE MARKET FORECASTS AND ANALYSIS
8.3. COMPENSATED CIRRHOSIS
8.3.1. Overview
8.3.2. Compensated cirrhosis Market Forecast and Analysis
8.4. DECOMPENSATED CIRRHOSIS
8.4.1. Overview
8.4.2. Decompensated cirrhosis Market Forecast and Analysis
9. LIVER CIRRHOSIS THERAPEUTICS DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG TYPE
9.1. OVERVIEW
9.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
9.3. URSODEOXYCHOLIC ACID
9.3.1. Overview
9.3.2. Ursodeoxycholic acid Market Forecast and Analysis
9.4. OBETICHOLIC ACID
9.4.1. Overview
9.4.2. Obeticholic acid Market Forecast and Analysis
9.5. AZATHIOPRINE
9.5.1. Overview
9.5.2. Azathioprine Market Forecast and Analysis
9.6. COLCHICINE
9.6.1. Overview
9.6.2. Colchicine Market Forecast and Analysis
9.7. OTHERS
9.7.1. Overview
9.7.2. Others Market Forecast and Analysis
10. LIVER CIRRHOSIS THERAPEUTICS DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
10.1. OVERVIEW
10.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
10.3. ORAL
10.3.1. Overview
10.3.2. Oral Market Forecast and Analysis
10.4. INTRAVENOUS
10.4.1. Overview
10.4.2. Intravenous Market Forecast and Analysis
10.5. OTHERS
10.5.1. Overview
10.5.2. Others Market Forecast and Analysis
11. LIVER CIRRHOSIS THERAPEUTICS DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - END USER
11.1. OVERVIEW
11.2. END USER MARKET FORECASTS AND ANALYSIS
11.3. HOSPITALS
11.3.1. Overview
11.3.2. Hospitals Market Forecast and Analysis
11.4. HOMECARE
11.4.1. Overview
11.4.2. Homecare Market Forecast and Analysis
11.5. SPECIALTY CLINICS
11.5.1. Overview
11.5.2. Specialty Clinics Market Forecast and Analysis
11.6. OTHERS
11.6.1. Overview
11.6.2. Others Market Forecast and Analysis

12. LIVER CIRRHOSIS THERAPEUTICS DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
12.1. NORTH AMERICA
12.1.1 North America Liver Cirrhosis Therapeutics Drugs Market Overview
12.1.2 North America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis
12.1.3 North America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Type
12.1.4 North America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Stage type
12.1.5 North America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Drug Type
12.1.6 North America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Route of Administration
12.1.7 North America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By End User
12.1.8 North America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Countries
12.1.8.1 United States Liver Cirrhosis Therapeutics Drugs Market
12.1.8.1.1 United States Liver Cirrhosis Therapeutics Drugs Market by Type
12.1.8.1.2 United States Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.1.8.1.3 United States Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.1.8.1.4 United States Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.1.8.1.5 United States Liver Cirrhosis Therapeutics Drugs Market by End User
12.1.8.2 Canada Liver Cirrhosis Therapeutics Drugs Market
12.1.8.2.1 Canada Liver Cirrhosis Therapeutics Drugs Market by Type
12.1.8.2.2 Canada Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.1.8.2.3 Canada Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.1.8.2.4 Canada Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.1.8.2.5 Canada Liver Cirrhosis Therapeutics Drugs Market by End User
12.1.8.3 Mexico Liver Cirrhosis Therapeutics Drugs Market
12.1.8.3.1 Mexico Liver Cirrhosis Therapeutics Drugs Market by Type
12.1.8.3.2 Mexico Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.1.8.3.3 Mexico Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.1.8.3.4 Mexico Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.1.8.3.5 Mexico Liver Cirrhosis Therapeutics Drugs Market by End User
12.2. EUROPE
12.2.1 Europe Liver Cirrhosis Therapeutics Drugs Market Overview
12.2.2 Europe Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis
12.2.3 Europe Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Type
12.2.4 Europe Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Stage type
12.2.5 Europe Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Drug Type
12.2.6 Europe Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Route of Administration
12.2.7 Europe Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By End User
12.2.8 Europe Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Countries
12.2.8.1 Germany Liver Cirrhosis Therapeutics Drugs Market
12.2.8.1.1 Germany Liver Cirrhosis Therapeutics Drugs Market by Type
12.2.8.1.2 Germany Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.2.8.1.3 Germany Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.2.8.1.4 Germany Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.2.8.1.5 Germany Liver Cirrhosis Therapeutics Drugs Market by End User
12.2.8.2 France Liver Cirrhosis Therapeutics Drugs Market
12.2.8.2.1 France Liver Cirrhosis Therapeutics Drugs Market by Type
12.2.8.2.2 France Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.2.8.2.3 France Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.2.8.2.4 France Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.2.8.2.5 France Liver Cirrhosis Therapeutics Drugs Market by End User
12.2.8.3 Italy Liver Cirrhosis Therapeutics Drugs Market
12.2.8.3.1 Italy Liver Cirrhosis Therapeutics Drugs Market by Type
12.2.8.3.2 Italy Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.2.8.3.3 Italy Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.2.8.3.4 Italy Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.2.8.3.5 Italy Liver Cirrhosis Therapeutics Drugs Market by End User
12.2.8.4 Spain Liver Cirrhosis Therapeutics Drugs Market
12.2.8.4.1 Spain Liver Cirrhosis Therapeutics Drugs Market by Type
12.2.8.4.2 Spain Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.2.8.4.3 Spain Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.2.8.4.4 Spain Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.2.8.4.5 Spain Liver Cirrhosis Therapeutics Drugs Market by End User
12.2.8.5 United Kingdom Liver Cirrhosis Therapeutics Drugs Market
12.2.8.5.1 United Kingdom Liver Cirrhosis Therapeutics Drugs Market by Type
12.2.8.5.2 United Kingdom Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.2.8.5.3 United Kingdom Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.2.8.5.4 United Kingdom Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.2.8.5.5 United Kingdom Liver Cirrhosis Therapeutics Drugs Market by End User
12.2.8.6 Rest of Europe Liver Cirrhosis Therapeutics Drugs Market
12.2.8.6.1 Rest of Europe Liver Cirrhosis Therapeutics Drugs Market by Type
12.2.8.6.2 Rest of Europe Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.2.8.6.3 Rest of Europe Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.2.8.6.4 Rest of Europe Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.2.8.6.5 Rest of Europe Liver Cirrhosis Therapeutics Drugs Market by End User
12.3. ASIA-PACIFIC
12.3.1 Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market Overview
12.3.2 Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis
12.3.3 Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Type
12.3.4 Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Stage type
12.3.5 Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Drug Type
12.3.6 Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Route of Administration
12.3.7 Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By End User
12.3.8 Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Countries
12.3.8.1 Australia Liver Cirrhosis Therapeutics Drugs Market
12.3.8.1.1 Australia Liver Cirrhosis Therapeutics Drugs Market by Type
12.3.8.1.2 Australia Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.3.8.1.3 Australia Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.3.8.1.4 Australia Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.3.8.1.5 Australia Liver Cirrhosis Therapeutics Drugs Market by End User
12.3.8.2 China Liver Cirrhosis Therapeutics Drugs Market
12.3.8.2.1 China Liver Cirrhosis Therapeutics Drugs Market by Type
12.3.8.2.2 China Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.3.8.2.3 China Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.3.8.2.4 China Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.3.8.2.5 China Liver Cirrhosis Therapeutics Drugs Market by End User
12.3.8.3 India Liver Cirrhosis Therapeutics Drugs Market
12.3.8.3.1 India Liver Cirrhosis Therapeutics Drugs Market by Type
12.3.8.3.2 India Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.3.8.3.3 India Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.3.8.3.4 India Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.3.8.3.5 India Liver Cirrhosis Therapeutics Drugs Market by End User
12.3.8.4 Japan Liver Cirrhosis Therapeutics Drugs Market
12.3.8.4.1 Japan Liver Cirrhosis Therapeutics Drugs Market by Type
12.3.8.4.2 Japan Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.3.8.4.3 Japan Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.3.8.4.4 Japan Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.3.8.4.5 Japan Liver Cirrhosis Therapeutics Drugs Market by End User
12.3.8.5 South Korea Liver Cirrhosis Therapeutics Drugs Market
12.3.8.5.1 South Korea Liver Cirrhosis Therapeutics Drugs Market by Type
12.3.8.5.2 South Korea Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.3.8.5.3 South Korea Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.3.8.5.4 South Korea Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.3.8.5.5 South Korea Liver Cirrhosis Therapeutics Drugs Market by End User
12.3.8.6 Rest of Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market
12.3.8.6.1 Rest of Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market by Type
12.3.8.6.2 Rest of Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.3.8.6.3 Rest of Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.3.8.6.4 Rest of Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.3.8.6.5 Rest of Asia-Pacific Liver Cirrhosis Therapeutics Drugs Market by End User
12.4. MIDDLE EAST AND AFRICA
12.4.1 Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market Overview
12.4.2 Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis
12.4.3 Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Type
12.4.4 Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Stage type
12.4.5 Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Drug Type
12.4.6 Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Route of Administration
12.4.7 Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By End User
12.4.8 Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Countries
12.4.8.1 South Africa Liver Cirrhosis Therapeutics Drugs Market
12.4.8.1.1 South Africa Liver Cirrhosis Therapeutics Drugs Market by Type
12.4.8.1.2 South Africa Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.4.8.1.3 South Africa Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.4.8.1.4 South Africa Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.4.8.1.5 South Africa Liver Cirrhosis Therapeutics Drugs Market by End User
12.4.8.2 Saudi Arabia Liver Cirrhosis Therapeutics Drugs Market
12.4.8.2.1 Saudi Arabia Liver Cirrhosis Therapeutics Drugs Market by Type
12.4.8.2.2 Saudi Arabia Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.4.8.2.3 Saudi Arabia Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.4.8.2.4 Saudi Arabia Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.4.8.2.5 Saudi Arabia Liver Cirrhosis Therapeutics Drugs Market by End User
12.4.8.3 U.A.E Liver Cirrhosis Therapeutics Drugs Market
12.4.8.3.1 U.A.E Liver Cirrhosis Therapeutics Drugs Market by Type
12.4.8.3.2 U.A.E Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.4.8.3.3 U.A.E Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.4.8.3.4 U.A.E Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.4.8.3.5 U.A.E Liver Cirrhosis Therapeutics Drugs Market by End User
12.4.8.4 Rest of Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market
12.4.8.4.1 Rest of Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market by Type
12.4.8.4.2 Rest of Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.4.8.4.3 Rest of Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.4.8.4.4 Rest of Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.4.8.4.5 Rest of Middle East and Africa Liver Cirrhosis Therapeutics Drugs Market by End User
12.5. SOUTH AND CENTRAL AMERICA
12.5.1 South and Central America Liver Cirrhosis Therapeutics Drugs Market Overview
12.5.2 South and Central America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis
12.5.3 South and Central America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Type
12.5.4 South and Central America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Stage type
12.5.5 South and Central America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Drug Type
12.5.6 South and Central America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Route of Administration
12.5.7 South and Central America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By End User
12.5.8 South and Central America Liver Cirrhosis Therapeutics Drugs Market Forecasts and Analysis - By Countries
12.5.8.1 Brazil Liver Cirrhosis Therapeutics Drugs Market
12.5.8.1.1 Brazil Liver Cirrhosis Therapeutics Drugs Market by Type
12.5.8.1.2 Brazil Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.5.8.1.3 Brazil Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.5.8.1.4 Brazil Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.5.8.1.5 Brazil Liver Cirrhosis Therapeutics Drugs Market by End User
12.5.8.2 Argentina Liver Cirrhosis Therapeutics Drugs Market
12.5.8.2.1 Argentina Liver Cirrhosis Therapeutics Drugs Market by Type
12.5.8.2.2 Argentina Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.5.8.2.3 Argentina Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.5.8.2.4 Argentina Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.5.8.2.5 Argentina Liver Cirrhosis Therapeutics Drugs Market by End User
12.5.8.3 Rest of South and Central America Liver Cirrhosis Therapeutics Drugs Market
12.5.8.3.1 Rest of South and Central America Liver Cirrhosis Therapeutics Drugs Market by Type
12.5.8.3.2 Rest of South and Central America Liver Cirrhosis Therapeutics Drugs Market by Stage type
12.5.8.3.3 Rest of South and Central America Liver Cirrhosis Therapeutics Drugs Market by Drug Type
12.5.8.3.4 Rest of South and Central America Liver Cirrhosis Therapeutics Drugs Market by Route of Administration
12.5.8.3.5 Rest of South and Central America Liver Cirrhosis Therapeutics Drugs Market by End User

13. INDUSTRY LANDSCAPE
13.1. MERGERS AND ACQUISITIONS
13.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
13.3. NEW PRODUCT LAUNCHES
13.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

14. LIVER CIRRHOSIS THERAPEUTICS DRUGS MARKET, KEY COMPANY PROFILES
14.1. GILEAD SCIENCES, INC
14.1.1. Key Facts
14.1.2. Business Description
14.1.3. Products and Services
14.1.4. Financial Overview
14.1.5. SWOT Analysis
14.1.6. Key Developments
14.2. INTERCEPT PHARMACEUTICALS, INC
14.2.1. Key Facts
14.2.2. Business Description
14.2.3. Products and Services
14.2.4. Financial Overview
14.2.5. SWOT Analysis
14.2.6. Key Developments
14.3. DOVA PHARMACEUTICALS
14.3.1. Key Facts
14.3.2. Business Description
14.3.3. Products and Services
14.3.4. Financial Overview
14.3.5. SWOT Analysis
14.3.6. Key Developments
14.4. GLAXOSMITHKLINE PLC
14.4.1. Key Facts
14.4.2. Business Description
14.4.3. Products and Services
14.4.4. Financial Overview
14.4.5. SWOT Analysis
14.4.6. Key Developments
14.5. REGENERON PHARMACEUTICALS
14.5.1. Key Facts
14.5.2. Business Description
14.5.3. Products and Services
14.5.4. Financial Overview
14.5.5. SWOT Analysis
14.5.6. Key Developments
14.6. MYLAN N.V
14.6.1. Key Facts
14.6.2. Business Description
14.6.3. Products and Services
14.6.4. Financial Overview
14.6.5. SWOT Analysis
14.6.6. Key Developments
14.7. SANOFI S.A
14.7.1. Key Facts
14.7.2. Business Description
14.7.3. Products and Services
14.7.4. Financial Overview
14.7.5. SWOT Analysis
14.7.6. Key Developments
14.8. TEVA PHARMACEUTICAL INDUSTRIES LTD
14.8.1. Key Facts
14.8.2. Business Description
14.8.3. Products and Services
14.8.4. Financial Overview
14.8.5. SWOT Analysis
14.8.6. Key Developments
14.9. F. HOFFMANN-LA ROCHE LTD
14.9.1. Key Facts
14.9.2. Business Description
14.9.3. Products and Services
14.9.4. Financial Overview
14.9.5. SWOT Analysis
14.9.6. Key Developments
14.10. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.10.1. Key Facts
14.10.2. Business Description
14.10.3. Products and Services
14.10.4. Financial Overview
14.10.5. SWOT Analysis
14.10.6. Key Developments

15. APPENDIX
15.1. ABOUT THE INSIGHT PARTNERS
15.2. GLOSSARY OF TERMS
The List of Companies

1. Gilead Sciences, Inc
2. Intercept Pharmaceuticals, Inc
3. Dova Pharmaceuticals
4. GlaxoSmithKline Plc
5. Regeneron Pharmaceuticals
6. Mylan N.V
7. Sanofi S.A
8. Teva Pharmaceutical Industries Ltd
9. F. Hoffmann-La Roche Ltd
10. Boehringer Ingelheim International GmbH

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Liver Cirrhosis Therapeutics Drugs Market